Supriya Lifescience logo

Supriya Lifescience financials and balance sheet

NSE: SUPRIYABSE: 543434Pharmaceuticals & BiotechnologySmall Cap

Last close ₹818.55down ₹17.70 (2.12%)BSE ₹818.90

Share price at the NSE close on 23 Oct 2026. Previous close ₹836.25.

52-week range of traded prices to 23 Oct 2026
₹545.50Low, 24 Mar 2026₹1,085.00High, 1 Jun 2026
Market cap
₹6,588 Cr733rd largest listed
P/E
33.2
P/B
5.5
Dividend yield
0.12%
ROE
18.1%
ROCE
21.6%
Debt to equity
0.00
Volume, NSE
1,62,92342.0% delivered

5 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Supriya Lifescience annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹828 Cr, year to Mar 2026

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue828
  2. Materials and goods−254
  3. Employee costs−97
  4. Other expenses−183
  5. Operating profit294
  6. Depreciation−28
  7. Other income+11
  8. One-off items−0.5
  9. Finance costs−1.9
  10. Profit before tax275
  11. Tax−66
  12. Net profit209

What the company owns

  • Plant, investments and other assets₹899 Cr
  • Receivables₹219 Cr
  • Inventory₹160 Cr
  • Cash and bank₹79 Cr

What pays for it: net worth and liabilities

  • Net worth₹1,198 Cr
  • Owed to suppliers₹111 Cr
  • Other liabilities₹49 Cr

Profit and loss

Standalone, ₹ crore, years to March.Supriya Lifescience quarterly results

₹ croreMar 2022Filed 24 MayMar 2023Filed 27 MayMar 2024Filed 11 JunMar 2025Filed 12 JunMar 2026Filed 27 May
Revenue from operations530461570696828
316332397436534
Materials and goods bought196181222211254
Employee costs4956688197
Other expenses7196108144183
Operating profit before depreciation214129173261294
Operating margin40.4%28.0%30.3%37.4%35.5%
Materials, % of revenue36.9%39.2%38.9%30.3%30.7%
Employee costs, % of revenue9.3%12.1%11.9%11.6%11.7%
Other expenses, % of revenue13.4%20.8%18.9%20.7%22.1%
Depreciation and amortisation1012162028
Operating profit after depreciation204117157240266
Other income89111011
Finance costs43222
Profit before one-off items and tax207123166248275
One-off items00000
Profit before tax207123166248275
5534476166
Net profit15290119188209
Other comprehensive income0−1200
Total comprehensive income15189121188209
Net margin28.6%19.5%20.9%27.0%25.3%

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2022Filed 24 MayMar 2023Filed 27 MayMar 2024Filed 11 JunMar 2025Filed 12 JunMar 2026Filed 27 May
6166998159971,198
Share capital1616161616
Reserves6006837999811,182
Borrowings2117000
100967782121
1925293338
Total assets7358209211,1121,357
237355523675825
498465398437532
Net debt−207−141−75−79−79
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2022Filed 24 MayMar 2023Filed 27 MayMar 2024Filed 11 JunMar 2025Filed 12 JunMar 2026Filed 27 May
4966113165186
11095151224247
−104−36−17−38−47
Receivables−4231−27−23−85
Inventories−20−2331−33−41
Payables−215−51536
Other working capital−41−58−16243
Tax paid−61−29−38−59−61
Capital spending60108146162152
Free cash flow−11−42−32234
−60−133−174−152−176
150−3−22−8−10
Dividends paid45568
Shares bought back00000
Shares issued2000000
Net change in cash139−70−8340
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Standalone, ₹ per share, years to March.Supriya Lifescience dividend history

₹ per shareMar 2022Filed 24 MayMar 2023Filed 27 MayMar 2024Filed 11 JunMar 2025Filed 12 JunMar 2026Filed 27 May
Earnings per share₹18.86₹11.16₹14.80₹23.35₹25.98
Diluted earnings per share₹18.86₹11.16₹14.80₹23.35₹25.98
Dividend per share₹0.60₹0.60₹0.80₹1.00₹1.00
Book value per share₹76.50₹86.91₹101.31₹123.84₹148.81
Dividend payout3.2%5.4%5.4%4.3%3.8%
Shareholder yield−4.9%0.3%0.2%0.1%0.2%
Market cap at the year end (₹ crore)3,9701,5352,6805,9094,522

Ratios

Standalone, years to March.Supriya Lifescience PE ratio and valuation

RatioMar 2022Filed 24 MayMar 2023Filed 27 MayMar 2024Filed 11 JunMar 2025Filed 12 JunMar 2026Filed 27 May
Revenue growth–−13.0%23.7%22.1%18.9%
Operating profit growth–−39.8%34.2%50.8%12.8%
Net profit growth–−40.8%32.6%57.8%11.3%
Earnings per share growth–−40.8%32.6%57.8%11.3%
24.7%13.7%15.7%20.7%19.1%
–−11.0 pts2.1 pts5.0 pts−1.7 pts
From the net margin–−7.9 pts1.0 pts4.6 pts−1.3 pts
From asset turnover–−3.0 pts1.5 pts0.9 pts−0.4 pts
From borrowing–−0.1 pts−0.4 pts−0.5 pts0.1 pts
Return on capital employed32.0%16.4%19.3%24.1%22.2%
Cash conversion32.1%73.7%95.1%87.6%88.8%
Interest cover48.638.074.5142.6140.6
Debt to equity0.030.020.000.000.00
Receivable days7967717097
Inventory days172234140205229
Payable days91130980159
Cash conversion cycle, days160171114275167
Working capital days132181157144147
Asset turnover0.720.590.660.690.67
Assets per rupee of net worth1.191.181.151.121.13
Sales per rupee of plant2.901.811.881.541.21
Capital spending to depreciation5.929.179.217.945.36
Plant being built, % of plant in use23.8%26.5%49.0%32.8%5.2%

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
16.9%
Cash from operations against operating profit
63.2%
Measure5 years3 years
Revenue growth, yearly rate–21.6%
Profit growth, yearly rate–32.5%
Return on equity, average18.8%18.5%
Return on capital employed, average22.8%21.9%
Operating margin, average34.3%34.4%
Net margin, average24.3%24.4%
Asset turnover, average0.660.67
Cash conversion cycle, days, average177185
Interest cover, average88.8119.2
Debt to equity, average0.010.00

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations579464186
Cash from investing−695−502−176
Cash from financing106−40−10
Capital spending629460152
Dividends paid29198
Shares bought back000
Shares issued for cash20000
Borrowings raised000
Borrowings repaid72192

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––773
Altman Z-scorePublished threshold 1.8123.4710.4018.0433.6719.89
Beneish M-scorePublished threshold −1.78–−2.49−1.71−2.28−2.27
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–20.1620.6017.2616.16
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––0.630.870.90
Receivables growth less revenue growthOur threshold 0 percentage points–−13.468.17−1.8044.46
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–33.07−49.0043.5914.56
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–9.713.32−3.01−3.67
Assets under construction, years of additionsOur threshold 2 years of additions–0.802.310.880.14
Effective tax ratePublished threshold 17.16 per cent26.7527.2328.1124.3623.90
Tax charged less tax paid, % of profitOur threshold 10 percentage points−2.673.875.390.541.55
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
6 Mar 2026ICRA Limited (opens in a new tab)Non-fund based-Others[ICRA]A1Review, Other10
6 Mar 2026ICRA Limited (opens in a new tab)Interchangeable limits-Others[ICRA]A1Review, Other34
6 Mar 2026ICRA Limited (opens in a new tab)Fund-based-Others[ICRA]A1Review, Other30
6 Mar 2026ICRA Limited (opens in a new tab)Interchangeable limits-Cash credit[ICRA]AReview, OtherPositive11
6 Mar 2026ICRA Limited (opens in a new tab)Fund-based-Cash credit[ICRA]AReview, OtherPositive74
30 Dec 2025India Ratings and Research Private Limited (opens in a new tab)Bank loan facilitiesIND A+; IND A1New, NewPositive114
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.